We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Corneal neovascularization and biological therapy.
- Authors
O. B., Voiculescu; L. M., Voinea; C., Alexandrescu
- Abstract
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions. Corneal neovascularization (NV) is a condition that can develop in response to inflammation, hypoxia, trauma, or limbal stem cell deficiency and it is a significant cause of blindness. New therapeutic options for diseases of the cornea and ocular surface are now being explored in experimental animals and clinical trials. Antibody based biologies are being tested for their ability to reduce blood and lymphatic vessel ingrowth into the cornea, and to reduce inflammation. Numerous studies have shown that biologies with specificity for VEGF A such as bevacizumab and ranibizumab (a recombinant antibody and an antibody fragment, respectively) or anti-tumor necrosis factor-a microantibody, are effective in the treatment of corneal neovascularization.
- Subjects
CORNEA injuries; NEOVASCULARIZATION; BLOOD-vessel development; STEM cell treatment; VISUAL optics
- Publication
Journal of Medicine & Life, 2015, Vol 8, Issue 4, p444
- ISSN
1844-122X
- Publication type
Article